Advancing Science Through Intelligent Systems

Helping researchers make informed decisions during the early stages of drug development.

Reimagining Scientific Workflows with AI

We own a pharmaceutical software artificial intelligence (“AI”) driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.

News and Highlights

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Mar 6, 2026

Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage...

View All News